Elevmi, a new app for Alzheimer’s caregivers, is now available in the Apple Store and Google Play Store. (Photo: Business Wire)
Elevmi™ harnesses the power of artificial intelligence (AI) to empower caregivers most affected by Alzheimer’s disease-related dementia
PRINCETON, N.J. and WILMINGTON, Del., October 7, 2024–(BUSINESS WIRE)–Otsuka Precision Health, Inc. (OPH) and Amalgam Rx, Inc. (Amalgam) announce the launch of Elevmi™ . An intelligent digital application that helps caregivers support loved ones with Alzheimer’s disease.
Caregivers are the foundation of Alzheimer’s disease patient care in our health care system. They often have well-paying jobs, busy lives, and responsibilities for maintaining their own health and mental well-being while providing dedicated care to their loved ones. A recent report published by the Alzheimer’s Association found that 7 in 10 dementia caregivers (70%) feel stressed coordinating care, and 2 in 3 caregivers (66%) also report struggling to find resources and support tailored to their needs. Elevmi™ changes the paradigm on how caregivers access information and receive support by harnessing the power of AI to provide curated, personalized context.
Today’s Alzheimer’s care is carried out by under-supported caregivers who need smart, immediate, and tangible support. According to the Alzheimer’s Association report, the top services for dementia caregivers include “24-hour support,” “care coordination,” and “understanding your loved one’s condition.” Elevmi™ bridges this gap.
“At OPH, we are committed to developing and expanding personalized solutions for the whole person that improve quality of life. “In addition to working on patient-centered solutions, Elebumi remains true to our mission of supporting whole-person care,” said OPH President Sanket Shah. . “We want to reduce stress and burden on caregivers by increasing their ability to manage and coordinate the care of those who rely on them, while directly supporting caregivers to improve their quality of life.” ”
Elevmi’s intuitive user experience is powered by a state-of-the-art large-scale language model (LLM) trained on content from the National Institute on Aging (NIA), part of the National Institutes of Health (NIH), and core PsychU. will be done. Online resources for mental health. Recognizing the challenges associated with treating Alzheimer’s disease, Elevmi™ makes it easier for caregivers to manage their loved one and understand their condition over time, while supporting their mental health and wellness. I’ll make it. Elevmi’s conversational AI capabilities allow caregivers to interact about their experiences, ask questions about their loved one’s condition, prepare for a doctor’s appointment, and more.
More than 300 real-life family caregivers supporting a loved one with Alzheimer’s disease participated in this research study, which helped identify and prioritize the app’s core features. Approximately 65 caregivers will participate in the product research committee and provide long-term feedback on the app’s branding, design, AI responses, and in-app content. “Developing solutions like Elevmi™ is core to our mission. It also represents the future of the healthcare industry,” said Shah. “We have a responsibility to build solutions that matter in ways that foster deeper connections for patients and the people who care for them. At OPH, we build these solutions and collaborate with best-in-class partners like Amalgam Rx across AI, mobile/web, and data science. , solving related problems in important ways.”
“Our North Star is, and always has been, to continue to improve patient care through better decision-making,” said Ryan Sisco, CEO of Amalgam Rx. “We take pride in pushing the boundaries of current models of care in a highly regulated and complex healthcare environment. There are many new entrants in the AI space; Amalgam has been developing medical-grade generative AI for years. Our AI platform works with our customers to build the right guardrails for life sciences and other healthcare companies. This is a great example of someone who has overcome challenges and responsibly brought real innovation to patients and caregivers.”
Elevmi™ is now available on iOS® and Android™ stores. Visit www.elevmi.com to download and learn more.
About Otsuka Precision Health Co., Ltd.
Combining the rigor of the pharmaceutical industry with a data-first focus on patient experience, Otsuka Precision Health Co., Ltd. (OPH) is focused on bringing prescription digital therapeutics and other innovative technologies to market. We provide patient support services that are not intended for. The company is working to personalize care, open doors to access, and unify fragmented experiences. OPH’s current areas of focus include a range of interventions that help uncover individuals’ health needs and address them as true collaborators within the broader healthcare ecosystem.
OPH is a subsidiary of Otsuka America Inc. (OAI). For more information, please visit www.okka-oph.com.
About Otsuka America, Inc.
Otsuka America, Inc. (OAI) is a holding company comprised of more than 20 group companies that provide innovative products to the pharmaceutical, nutraceutical and consumer markets. The Pharmaceutical segment discovers, develops and markets products focused on the diagnosis and treatment of diseases, primarily in the fields of neuroscience, nephrology and oncology. We are committed to developing digital innovations and medicines that enhance the patient experience and improve patient outcomes. The Nutraceuticals business is dedicated to maintaining and improving health through high-quality vitamins, minerals and supplements that provide complete nutrition. The consumer business is dedicated to providing the market with beverages that are not only refreshing and healthy, but also good for the environment and the communities that enjoy them. Following a pre-industrial winemaking approach, we produce award-winning, single-vineyard, organic, and sustainable wines. We are Otsuka employees who develop new products to improve health around the world.
OAI is a subsidiary of Otsuka Pharmaceutical Co., Ltd. headquartered in Tokyo. For more information, please visit www.okka-america.com.
About Amalgam Rx
AmalgamRx reimagines healthcare by empowering patients and providers to make the best possible decisions in provider workflows and patients’ daily lives. For more than 15 years, our team has reimagined care delivery and created lasting change across the chronic care ecosystem. Amalgam’s suite of AI-powered EHR solutions and SaMD platforms enable leading life sciences companies, health plans, and healthcare delivery organizations to collaborate and deliver better care. Today, Amalgam’s algorithms and applications support patients on four continents and have helped healthcare providers make more than 50 million decisions. Amalgam’s solution leverages billions of RWE streaming data points across the platform. To learn more about how Amalgam Rx’s regulated, clinically-validated technology brings patients and providers closer together, lowers costs for payers and unlocks lasting value for partners, please visit www. Visit amalgamrx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241007017878/en/
contact address
Otsuka in Japan
Jeffrey Gilbert (outside the US)
Pharmaceutical PR Leader
Otsuka Pharmaceutical Co., Ltd.
gilbert.jeffrey@okka.co.jp
Otsuka Precision Health
frank chavez
Head of Strategy and Corporate Development
Otsuka Precision Health Co., Ltd.
Frank.chavez@okka-oph.com
Amalgam Rx
Fred Garik
fgalik@amalgamrx.com
